Profile of Dr Anna Hine
Anna Hine gained her PhD in Molecular Biology from UMIST in 1993 and her postdoctoral training at Harvard Medical School (Principal Investigator (PI): Prof Charles C. Richardson). She returned to the UK to take up a lectureship in Molecular Biology at Aston University in 1995. In late 2003, she commenced her combined career in academia and innovation with a Medici Fellowship (commercialisation and entrepreneurial training), which was later followed by an 18 month secondment to the University's Business Partnership Unit as the School of Life and Health Sciences' Innovation Fellow. Resulting from numerous multi-disciplinary collaborations, her group invented ProxiMAX randoization - a novel saturation mutagenesis technology that both eliminates redundancy from synthetic gene libraries and allow a "pick and mix" designer approach to constructing protein libraries. This work is now available commercially via Isogenica Ltd., under the tradename "ColibraTM". Her other interdisciplinary interactions include exploiting protein-DNA interactions to achieve advances in biotech process engineering, development of photonic biosensors and most recently, a generic technology to deliver and release proteins within mammalian cells. Dr Hine was named "BBSRC Commercial Inovator of the Year 2013" in March.